Prognosis
Benefits of Pfizer Child Shot Likely Outweigh Risks, FDA Says
- Agency staff issues report ahead of advisory meeting Tuesday
- Mild side effects similar to those seen in adults after shot
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know
The staff of the Food and Drug Administration said the benefits of Pfizer Inc. and BioNTech SE’s Covid-19 vaccine for young children likely outweigh its risks, ahead of a meeting next week where experts will weigh whether the shot should be cleared for use.